In Defense of Phosphodiesterase 5 Inhibitors-Reply

Mohit Sodhi^{1

2}, Frederick S Mikelberg¹, Mahyar Etminan^{1

3}

Affiliations

¹ Collaboration for Epidemiology of Ocular Diseases, Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
² Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
³ Department of Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Comment

Mohit Sodhi et al. JAMA Ophthalmol. 2022.

. 2022 Sep 1;140(9):908-909.

doi: 10.1001/jamaophthalmol.2022.2615.

Mohit Sodhi^{1

2}, Frederick S Mikelberg¹, Mahyar Etminan^{1

3}

¹ Collaboration for Epidemiology of Ocular Diseases, Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
² Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
³ Department of Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

No abstract available

Comment on

Risk of Ocular Adverse Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in the US.
Etminan M, Sodhi M, Mikelberg FS, Maberley D. Etminan M, et al. JAMA Ophthalmol. 2022 May 1;140(5):480-484. doi: 10.1001/jamaophthalmol.2022.0663. JAMA Ophthalmol. 2022. PMID: 35389459 Free PMC article.
In Defense of Phosphodiesterase 5 Inhibitors.
Belladelli F, Del Giudice F, Eisenberg ML. Belladelli F, et al. JAMA Ophthalmol. 2022 Sep 1;140(9):908. doi: 10.1001/jamaophthalmol.2022.2612. JAMA Ophthalmol. 2022. PMID: 35862053 No abstract available.